Financials
Financial year 2025
Gross margin
€ 0
Profit
Growing€ 5.8 million
▲ 1332% vs 2024
Debts
Low€ 2,100
▼ 14% vs 2024
UCB Fipar from Anderlecht, company number BE0403198811, closed financial year 2025 with a result of € 5.8 million after tax. For that financial year UCB Fipar recorded a gross margin of € 0 and equity of € 38.6 million. Compared with financial year 2024, the result moved from € 407,938 to € 5.8 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 20, 2026.
What happened at UCB Fipar?
What happened at UCB Fipar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 5.8 million (▲ 1332% vs 2024). Source: NBB ↗
- Jean-Christophe TELLIER stepped down as director. NBB
- Sandrine DUFOUR stepped down as director. NBB
- Loïc HAMEON stepped down as director. NBB
- Denelle J. WAYNICK JOHNSON stepped down as director. NBB
- Denelle J. WAYNICK JOHNSON became a director. NBB
- Jean-Christophe TELLIER became a director. NBB
- Sandrine DUFOUR became a director. NBB
In short
From € 1.2 million loss in 2021 to € 5.8 million profit in 2025.
Paid € 6,642 in corporate taxes since 2021.
Best year ever: 2025, with € 5.8 million profit.
Paid out € 80 million in dividends to the owners in total.
A new publication or filing at UCB Fipar? We notify you, reason included.
Follow UCB FiparNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by UCB BELGIUM SA (100%). It owns 42% of EpilepsyGTx, 33.8% of BlueHealth Innovation Fund, 7.9% of Neurava, Inc., 6.8% of IMIDomics Inc., 3.7% of Bingli and 1.7% of UCB Pharma Lda itself.
Directors
According to the 2025 annual accounts
since 2022 · until 2026
since 2022 · until 2026
Loïc HAMEON
Director
since 2022 · until 2026
Denelle J. WAYNICK JOHNSON
Director
Also active at: UCB BIOPHARMA, UCB Ventures, UCB Ventures Belgium
since 2023 · until 2026
Shareholders
100%
Participations
EpilepsyGTx
42%
Neurava, Inc.
7.9%
IMIDomics Inc.
6.8%
3.7%
UCB Pharma Lda
1.7%
EYSZ Inc
1%
UCB A.E. (Greece)
0.2%
UCB Pharma S.P.A. (Italy)
0.1%
0%
UCB De Mexico S.A. de C.V.
0%
UCB Biopharma S.A.
0%
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
UCB Belgium same network
U C B
UCB PHARMA same network
€ 4,622.6 million revenue · 2025
Fondation Emmanuel Janssen
UCB BIOPHARMA same network
€ 3,642.1 million revenue · 2025
+5 more
Details
- Company number
- 0403.198.811
- VAT number
- BE 0403.198.811
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB Fipar
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 November 1947
- Peppol
- Not registered